Search

Displaying results 871 - 880 of 2815 in total
  1. Drug

    PD-98059

    go.drugbank.com/drugs/DB17042
    Experimental

    PD-98059 is an inhibitor of MAP-kinase kinase activation.[A253072]

  2. Drug

    PF-04447943

    go.drugbank.com/drugs/DB11953
    Investigational

    PF-04447943 has been investigated for the treatment of Alzheimer's Disease.

  3. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

  4. Drug

    Biropepimut-S

    go.drugbank.com/drugs/DB14816
    Investigational

    Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral

    Synonyms: LYS-VAL-ALA-GLU-LEU-VAL-HIS-PHE-LEU-ARG-VAL-LYS-ARG-PHE-LEU-TRP-GLY-PRO-ARG-ALA-LEU-VAL-ARG-VAL-LYS-ARG-VAL-ILE-PHE-SER-LYS-ALA-SER-SER-SER-LEU-GLN-LEU-ARG-LYS-LYS-ARG-ARG-GLN-ARG-ARG-ARG
  5. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

    Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index
  6. Drug

    PF-00217830

    go.drugbank.com/drugs/DB12998
    Investigational

    PF-00217830 has been used in trials studying the treatment of Schizophrenia.

  7. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia (HoFH) under the brand

  8. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: IVABRADINA DOC GENERICI
  10. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    The main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. … The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875].